Sato Pharmaceutical Launches Thyroid Cancer Diagnostic Aid Thyrogen
This article was originally published in PharmAsia News
Executive Summary
Sato Pharmaceutical announced the company will launch Thyrogen (thyrotropin alfa) Jan. 13. Approved by Japan's Ministry of Health, Labor and Welfare last October, Thyrogen is a thyroid cancer diagnostic aid for the patients after a surgery. The drug is Sato's first biopharmaceutical and oncology product, and the company plans to expand market share in the area and plans to make it another profit pillow after its over-the-counter drug business. (Click here for more - Japanese language
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.